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Figure 2 Determining the optimal 
dosage of G418 (μg/mL) for 
selection of Panc02 cells. After five 
days in 400 μg/mL, all cells died. 
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Introduction
Hormone receptor positive (HR+) breast cancer patients have an excellent prognosis with over 85% cure rates. However, 20,000 women 
with HR+ breast cancer die annually from tumor recurrence. Those at highest risk for recurrence are those women whose tumors 
continue to proliferate through estrogen blockade (Figure 4). Addition of chemotherapy for these patients failed to improve outcomes. 
We retrospectively identified women with HR+ breast cancer treated neoadjuvantly with aromatase inhibitors (AI), and selected matched 
patient cohorts for responders and non-responders determined by post-AI Ki67 of <10% or ≥10%. The pathology and molecular 
genomics core extracted RNA from FFPE slides from the surgical resection tissue and performed Nanostring sequencing using the Pan 
Cancer IO 360 panel, Breast Cancer 360 panel, and custom probes totaling 1,249 sequenced transcripts. We proposed to utilize this 
Nanostring analysis to identify drug able immuno-oncology targets to improve outcomes for these women at high risk of recurrence. 
Materials and Methods 
We used the Nanostring technology, nSolver to normalize our RNA
count data. We then used R to generate heat maps and differential
expression plots. Using the fold change determined on nSolver, we
used Cytoscape and Reactome pathway visualization software to
create pathway maps.
Conclusions 
In non-responders, genes regulating to cell cycle an DNA repair 
were upregulated. In responders, genes regulating endothelial 
mesenchymal transition, cytokine signaling, chemokine signaling, 
and angiogenesis were slightly upregulated.
Introduction
It is difficult to accurately in vivo image orthotopic tumors using CT scans alone. Muriglo provides the capability to visualize in vivo 
bioluminescent signals emanating from intact tissues. We can coregister CT scans captured with the SARRP with luciferase signals 
captured with the Muriglo and locate tumor isocenters for image-guided radiation. We may then direct radiation to neoplastic tissue while 
also sparing the maximum amount of healthy tissue. To do this we must genetically engineer cells to express luciferase. We propose a 
protocol to use a retrovirus to create stable cell lines that express firefly luciferase for bioluminescence. We will also determine the 
optimal dosage of the G418 antibiotic for selection.
Materials and Methods 
Retroviral Transfection
We first infected HEK293T cells using 
pcDNA3 gag pol, phCMV6 VSVG, 
and Luciferase mCherry plasmids and 
the transfecting reagent, 
Lipofectamine 3000. After 18 hours, 
we replaced the media (10% FBS). 
48-72 hours later, we harvested the 
viral supernatant. We then filtered the 
supernatant using a 45-micron 
syringe filter and promptly froze the 
filtrate in -80º C. We assessed 
transfection efficiency with flow 
cytometry.
Determining G418 Dose for 
Selection
We grew Panc02 cells in a six well 
plate up to 80 percent confluence. We 
then replaced the media with media 
containing variant concentrations of 
our selection antibiotic, G418. After 
five days incubating at 37º C 5% CO2, 
we took images and determined an 
appropriate concentration of G418 by 
finding the lowest concentration that 
killed all cells. 
Retroviral Transduction
In a six well plate, we put different 
dilutions of the viral supernatant 
produced by the HEK293T cells in  
DMEM 10% FBS without penicillin 
streptomycin and Polybrene (10 
μg/mL). Roughly 5 x 104 Panc02 cells 
were then placed into each well and 
the cells were incubated for 48-72 
hours. We assessed transduction 
efficiency with flow cytometry.
AM12 gp Transfection
We seeded AM12 cells into four 10cm 
dishes at a density of 4 x 106 cells 
per 8mL DMEM 10% FBS wit 
penicillin and streptomycin. We then 
added 400 μL of LyoVecTM with 12 μg 
of GFP and mCherry Plasmid DNA to 
each dish according to the LyoVecTM
protocol.
Conclusions
Using flow cytometry, we were able 
to verify that we successfully 
transfected the mCherry plasmid 
into HEK293T cells. Based on our 
G418 toxicity test (Figure 2), over 
200 μg/mL of G418 can be used for 
selection of Pano02 cells. We also 
found that AM12 cells can easily be 
transfected to produce virus.
Future Research
Create stable cell lines that can 
express a bioluminescent marker 
Trials involving in vivo imaging of 
bioluminescent tumors using SARP 
and Muriglo.
Figure 4 Time since 
registration vs. recurrence-
free survival. Five years after 
registration, patients with ≤ 
10% Ki67 have a higher 
percentage of Recurrence-
Free Survival than ≥ 10% 
Ki67 patients.
Figure 5 Cytoscape Reactome pathway visualization. Sizes of 
circles were determined by fold change.  Interactor genes are 
labeled in red. All genes here are threshold by an adjusted p-
value of 0.1. 
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Figure 1 Flow Cytometry of Transfected HEK293T cells. The mCherry positive counts in the 
PE-A channel suggest that some HEK293T cells were successfully transfected. The viral 
supernatant collected from this sample however, did not successfully transduce Panc02 target 
cells.
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Figure 7 Differential expression of genes between cohorts. 
Statistically significant genes were mainly downregulated in 
the responder cohort. 
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Figure 3 GFP Expression in transfected AM12 cells. 
Green signals indicate successfully transfected 
AM12 cells.  Toxicity is suggested by the large 
population of dead cells. Photo was taking with 10x 
magnification. 
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Figure 6 Heatmap of ER pathway genes vs. patient pairings 
shows upregulation of DNA Damage genes and 
downregulation of angiogenesis genes in non-responders.  
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